$45.07
0.721.62%
At Close: -
$44.43
-0.64-1.42%
After Hours: 4:28 PM EDT
15 minutes delayed
Disc Medicine
IRONNASDAQ
Disc Medicine (NASDAQ:IRON) Stock, Analyst Ratings, Price Targets, Predictions
Disc Medicine Inc has a consensus price target of $56.63, established from looking at the 35 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, HC Wainwright & Co., and Cantor Fitzgerald on June 17, 2024, June 14, 2024, and May 28, 2024. With an average price target of $75 between BMO Capital, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 68.80% upside for Disc Medicine Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
HC Wainwright & Co.
Cantor Fitzgerald
Raymond James
Stifel
1calculated from analyst ratings
Analyst Ratings for Disc Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/17/2024 | Buy Now | 57.55% | BMO Capital | Evan Seigerman | $50 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 06/14/2024 | Buy Now | 57.55% | HC Wainwright & Co. | Douglas Tsao | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 91.31% | Cantor Fitzgerald | Kristen Kluska | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 05/15/2024 | Buy Now | 91.31% | Cantor Fitzgerald | Kristen Kluska | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2024 | Buy Now | 57.55% | HC Wainwright & Co. | Douglas Tsao | → $70 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | -3.22% | Raymond James | Danielle Brill | $40 → $43 | Maintains | Outperform | Get Alert |
| 04/08/2024 | Buy Now | 64.3% | Stifel | Benjamin Burnett | $71 → $73 | Maintains | Buy | Get Alert |
| 04/02/2024 | Buy Now | -9.97% | Morgan Stanley | Jeffrey Hung | $75 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/02/2024 | Buy Now | 12.54% | BMO Capital | Evan Seigerman | — | Maintains | Outperform | Get Alert |
| 04/02/2024 | Buy Now | 59.8% | Stifel | Benjamin Burnett | $104 → $71 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | -9.97% | Raymond James | Danielle Brill | → $40 | Downgrade | Strong Buy → Outperform | Get Alert |
| 04/01/2024 | Buy Now | 57.55% | HC Wainwright & Co. | Douglas Tsao | → $70 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 57.55% | HC Wainwright & Co. | Douglas Tsao | $70 → $70 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 134.08% | Stifel | Benjamin Burnett | $76 → $104 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 80.06% | BMO Capital | Evan Seigerman | $70 → $80 | Maintains | Outperform | Get Alert |
| 12/20/2023 | Buy Now | 91.31% | Cantor Fitzgerald | Kristen Kluska | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | 46.3% | Morgan Stanley | Jeffrey Hung | $56 → $65 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/14/2023 | Buy Now | 57.55% | HC Wainwright & Co. | Douglas Tsao | $66 → $70 | Maintains | Buy | Get Alert |
| 06/12/2023 | Buy Now | 26.04% | Morgan Stanley | Jeffrey Hung | $37 → $56 | Maintains | Overweight | Get Alert |
| 06/12/2023 | Buy Now | 57.55% | BMO Capital | Evan Seigerman | $40 → $70 | Maintains | Outperform | Get Alert |
| 06/12/2023 | Buy Now | 68.8% | Raymond James | Danielle Brill | $50 → $75 | Upgrade | Outperform → Strong Buy | Get Alert |
| 06/09/2023 | Buy Now | 12.54% | Stifel | Benjamin Burnett | $40 → $50 | Maintains | Buy | Get Alert |
| 06/09/2023 | Buy Now | 46.3% | Cantor Fitzgerald | Kristen Kluska | $45 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/09/2023 | Buy Now | 68.8% | Raymond James | Danielle Brill | $50 → $75 | Upgrade | Outperform → Strong Buy | Get Alert |
| 06/09/2023 | Buy Now | 48.55% | HC Wainwright & Co. | Douglas Tsao | $55 → $66 | Reiterates | → Buy | Get Alert |
| 06/07/2023 | Buy Now | 23.79% | HC Wainwright & Co. | Douglas Tsao | → $55 | Initiates | → Buy | Get Alert |
| 05/17/2023 | Buy Now | 12.54% | Raymond James | Danielle Brill | → $50 | Initiates | → Outperform | Get Alert |
| 04/28/2023 | Buy Now | 1.28% | Cantor Fitzgerald | Kristen Kluska | → $45 | Initiates | → Overweight | Get Alert |
| 04/26/2023 | Buy Now | -18.97% | Wedbush | David Nierengarten | $32 → $36 | Maintains | Outperform | Get Alert |
| 04/21/2023 | Buy Now | -16.72% | Morgan Stanley | Jeffrey Hung | → $37 | Reiterates | → Overweight | Get Alert |
| 04/21/2023 | Buy Now | -16.72% | Stifel | Benjamin Burnett | → $37 | Initiates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | -16.72% | Morgan Stanley | Jeffrey Hung | → $37 | Initiates | → Overweight | Get Alert |
| 03/23/2023 | Buy Now | -9.97% | BMO Capital | Evan Seigerman | → $40 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | -18.97% | SVB Leerink | Thomas Smith | → $36 | Initiates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | -32.48% | Wedbush | David Nierengarten | → $30 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Disc Medicine (IRON) stock?
The latest price target for Disc Medicine (NASDAQ:IRON) was reported by BMO Capital on June 17, 2024. The analyst firm set a price target for $70.00 expecting IRON to rise to within 12 months (a possible 57.55% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Disc Medicine (IRON)?
The latest analyst rating for Disc Medicine (NASDAQ:IRON) was provided by BMO Capital, and Disc Medicine reiterated their outperform rating.
When was the last upgrade for Disc Medicine (IRON)?
The last upgrade for Disc Medicine Inc happened on June 12, 2023 when Raymond James raised their price target to $75. Raymond James previously had an outperform for Disc Medicine Inc.
When was the last downgrade for Disc Medicine (IRON)?
The last downgrade for Disc Medicine Inc happened on April 1, 2024 when Raymond James changed their price target from $75 to $40 for Disc Medicine Inc.
When is the next analyst rating going to be posted or updated for Disc Medicine (IRON)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Disc Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Disc Medicine was filed on June 17, 2024 so you should expect the next rating to be made available sometime around June 17, 2025.
Is the Analyst Rating Disc Medicine (IRON) correct?
While ratings are subjective and will change, the latest Disc Medicine (IRON) rating was a reiterated with a price target of $50.00 to $70.00. The current price Disc Medicine (IRON) is trading at is $44.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.